



Pioneers bringing
pharmaceutical
industry expertise to the
world of medicinal cannabis

June 2017



Disclaimer



This presentation has been prepared by Creso Pharma Limited (Company or Creso). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso. This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.


US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.

Current Situation: Nascent Industry



- The medicinal cannabis industry is still in its infancy and dominated by small players with no pharmaceutical industry expertise
- This has led to questionable quality due to the lack of standardisation in formulation and dosage of cannabis derived products
- There is a remarkable lack of trusted cannabis brands in the global marketplace
- Established pharmaceutical companies are generally reluctant to enter the market due to evolving regulations

Creso brings significant pharmaceutical industry expertise and rigour to the world of medicinal cannabis



Creso Pharma Ltd: Company Summary ASX:CPH



CEO Headquartered in Zug, Switzerland 
COO based in Sydney, Australia 


Global development and commercialization of pharmaceutical grade cannabis and hemp derived therapeutic products using innovative delivery technologies

| | | |
|------------------------|-----|----------------------------------|
| Market Cap @ 44 cents* | \$m | 38.9m |
| Cash at Hand | \$m | ~10.5m |
| Enterprise value | \$m | ~28.4m |
| Shares on Issue | no. | 88.3m |
| Top 20 shareholders | % | 51.1% |
| Escrowed Shares | No. | 15.6m (29.9% of Shares On Issue) |

- Creso Pharma's offices are in Zug, Switzerland, Sydney and Perth
- Best-in-class with highest Good Manufacturing Practice (GMP) certified processes
- Standardised cannabis-based treatments that meet international pharmaceutical standards
- Novel and proprietary delivery technologies ensuring high bioavailability and absorption
- Focused on Medicinal Cannabis in Australia and being responsive to regulatory shifts
- European Nutraceutical products for both humans and companion animals

*Data as at May 29, 2017

Creso Pharma Ltd: Two distinct divisions



Creso Pharma Ltd: Mission Statement & Board



"Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products. It is the leader in cannabidiol (CBD) innovation and develops cannabis- and full plant hemp-derived therapeutic-grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health."



**Dr. Miri
Halperin Wernli**
CEO &
Co-Founder

Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries. She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US.



**Boaz
Wachtel**
Chairman & Co-
Founder

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland



Adam Blumenthal
Non-Executive
Director &
Co-Founder

Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.



**Dr. James
Ellingford**
Non-Executive
Director

Dr. Ellingford's professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.

Creso Pharma Ltd: Commercial/Market Access Advisors



David Russell
Chief Operating Officer

Mr. Russell has more than 25 years' experience within the pharmaceutical and biotech industry with a number of leading global companies including Roche, Actelion Pharmaceuticals, Celgene and Novogen (ASX:NRT). In particular, he has been responsible for building, leading and growing commercial teams resulting in multiple product launches in China, Australia and Asia in a number of therapeutic areas.



Jorge Wernli
Industry Advisor

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.



Dr. Gian Trepp
Industry Advisor

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.

Creso Pharma Ltd: Scientific Advisory Board



**Dr. Isaac
Kobrin**
Industry Advisor

Dr. Isaac Kobrin is an internist with 15 years experience in the academic medicine both in Israel and the USA. He has over 22 years of experience in the Pharma Industry in Roche and Actelion. He has been responsible for the worldwide development of key compounds and has held numerous leadership positions in medical organisations.



**Dr. Stéphane
Redey**
Industry Advisor

Dr. Stéphane Redey has over 18 years experience leading teams in the technical development of innovative drugs and strategic outsourcing. He has held senior positions with global responsibilities in pharmaceutical companies in both Switzerland and Australia. He has led successful international collaborations with companies on four continents.



**Dr. Raquel
Peyraube**
Industry Advisor


Dr. Raquel Peyraube is a specialist in the drug field with more than 28 years experience. Throughout her career she has been involved in training, prevention, treatment and harm reduction, developing innovative approaches emphasising ethical issues which has earned her international recognition. Dr Peyraube is currently a consultant on drug policy reform in Latin America.



**Prof. Dr. med Felix
Gutzwiller**
Industry Advisor

Felix Gutzwiller holds the titles of MD of the University of Basel, an MPH of the Harvard School of Public Health, Dr. PH of the Johns Hopkins University School of Hygiene and Public Health. He was a Professor at the University of Basel and a Professor of Social and Preventive Medicine at the University of Zürich (1988-2013), Emeritus since 2013.

Creso Pharma Ltd: Achievements since IPO



Creso Pharma Ltd: Investment Proposition



Fills void in current market with growing need for **trusted products** that meet the highest global pharmaceutical standards



Near-term revenues
Product launches in the EU of animal (2017) and human (2018) products



Growing market opportunity with **six plus products in pipeline** targeting human and animal nutraceutical markets



Exclusive licensing deals that gives Creso access to unique drug delivery IP



Diversified revenue stream targeting human and pet health markets



Large **global market** that is only at the start of its growth




Company well placed to be the **"gold standard"** in cannabis and hemp derived therapeutics



Why Cannabis?

Cannabidiol (CBD)

*Creso only uses **full plant extracts**. Cannabinoids and other compounds have a greater effect when taken together than when separated into individual compounds potentially **synergistically** to create the "**Entourage Effect**"*



1.

Therapeutic benefits

- Anti-inflammatory
- Anti-convulsant
- Anti-oxidant
- Anti-emetic
- Anxiolytic
- Anti-psychotic

2.

Potential treatment of:

- Anxiety/Stress Disorders
- Metabolic: Diabetes
- Neuro inflammation
- Neurological: Epilepsy
- Nausea
- Schizophrenia

3.

For pets:

- Animal studies suggest that CBD may have anti-inflammatory effects, may stimulate and regulate appetite, and may modulate anxiety and pain – without psychoactive effects




Vast Market Potential

Rapidly Growing Markets as Regulations Evolve

- No data exists for Australian potential
- **Global:** Sales now exceeding \$4.5 billion
- **US:** A 3 million-patient market opportunity (More than 700K patients have already been prescribed)
- **Canada:** Estimated at \$144 million in 2014, rising to \$380 million by 2018, to \$1.3 billion in the next 10 years
- **Europe:** Vast unmet demand. Small quantities usually imported from Holland's only national medical-grade cannabis (MGC) program supplier - Bedrocan.

US\$ Marijuana Sales Estimates



| Country | Market Size |
|------------------|-------------|
| U.S. | \$6.4B |
| Canada | \$0.18B |
| Europe | \$7.53B |
| Australia (Est.) | \$0.150B |

Growth in Human Health Markets



Nutraceuticals are a multi-billion dollar industry

- Total global nutraceuticals market reached **\$142.1 billion** in 2011
- Expected to reach **\$204.8 billion** by 2017
- The nutraceutical ingredient market is forecast to reach \$33.6 billion by 2018
- The overall US nutrition market was estimated at **\$137.4 billion** in 2012, with supplements accounting for **\$32.4 billion**



Multiple drivers for continued growth

- Rising health concerns, the growth of key demographics and growing consumer desire to lead a healthy life and avoid dependence on synthetic drugs are identified trends that show no sign of slowing down



Extremely lucrative for food and beverage companies

- Comparatively high margins
- Minimal regulatory requirements
- Germany, Switzerland, Netherlands, and Sweden have emerged as the key nutraceutical innovation hubs in Europe

Creso Pharma Ltd: Filling Unmet Need in the Market



The market for nutraceutical cannabinoids is still untapped

1

Generally, no GMP-certified production to produce standardized high-grade plant extracts

2

Lack of efficacious delivery systems to ensure sufficiently high bioavailability

3

Lack of seasoned pharmaceutical executives to develop products and launch brands in this area




The Creso Advantage

Creso: Product Pipeline



- Ready for launch
- Launch




* PPS = Prairie Plant Systems Canada/Cannapharm AG

Creso: Unique Delivery Technologies

Creso has exclusive world-wide use of two rapidly absorbed oral/buccal delivery technologies for cannabis treatments through licensing deals with:

| INNutri Soft Gums™ | BioLingus™ (Sublingual Tablets) |
|--|---|
| <p>Innovative soft chewable gums with a fillable center made of starch (not from animal material such as gelatin like other gums).</p> | <p>Novel proprietary platform for sublingual delivery of bio-active molecules for chronic diseases and immune-therapies.</p> |
| <ul style="list-style-type: none"> ✓ Easy to ingest ✓ 60% cheaper than the gelatin capsules ✓ Choice of flavours ✓ Have non-sticky texture compared to other vegetarian products (starch, pectin) ✓ Vegan, Halal and Kosher ✓ Suited for geriatric and pediatric use ✓ Heat resistant technology ✓ Gluten and Lactose free | <ul style="list-style-type: none"> ✓ Optimised and stable pill ✓ Robust manufacturing process ✓ Similar efficiency to subcutaneous injection in mice ✓ Highly scalable production process ✓ Relatively low cost ✓ Long shelf life |



Creso: Animal Health Nutraceutical Products



Creso has four animal health feed nutraceutical products for Large Animals and small companion animals.

Launch planned for Q3 2017 and Q1 2018

1

One product is aimed at large animals (horses where regulatory possible) which mainly targets stress, chronic joint pain and arthritis

2

Second product is aimed at small companion animals (e.g. dogs) which mainly targets behavioural problems and pain and senior animals with chronic joint pain and arthritis

- Globally 33% of households have a dog¹
- The recession-resistant animal health products industry is projected to continue showing rapid growth
- One of the biggest challenges of pet ownership is maintaining pets health
- 41% of pet owners have considered or tried various alternative therapies including:
 - Nutritional supplements (29%)
 - Herbal remedies (7%)
 - Homeopathy (4%)

In Australia: Medicinal Cannabis

Creso is first to offer imported medicinal cannabis products to the Australian market following recent changes to Government legislation

- Creso Pharma's Australian partner, Health House International, successfully imported the first medicinal cannabis products into Australia in May 2017 following changes to Government legislation
- Import was a range of three cannabis oils for human health from Canadian manufacturer CanniMed
- The oils can be used for a variety of conditions as approved by prescribing physicians under Australian Federal and State laws and regulations to meet immediate need for medicinal cannabis locally
- Products will now be distributed to authorised pharmacies by Health House with Creso receiving a facilitation fee for all products sold in Australia



In Australia: Medicinal Cannabis

LOI Signed with Cannapharm AG, Switzerland

- Two Forms – Tincture and Oil
- THC/CBD
 - 10:20 in the alcohol extraction
 - 10:25 in the hemp oil extraction
- Exclusive Territory: Australia, New Zealand, China, Brazil, Mexico, Chile, Colombia



Creso Pharma Ltd: Comprehensive Approach




Hemp based full-plant medical grade CBD-rich nutraceutical products which are efficacious, safe, standardised in composition and dose

A nutraceutical approach for both human and vet markets

- 1 **GMP sourcing only:** nutraceutical products from GMP-certified plants located in Europe, syndicated to our needs
- 2 **Standardized extraction:** GMP- and/or ISO-compliant extraction processes, to supply products of excellent quality, purity, and safety
- 3 **Owning and developing unique delivery methods:** source and license innovative and proven delivery platforms including tablets and sublinguals to increase absorption and bioavailability
- 4 **Sales channels:** Will not be sold online but will be registered with health authorities with full registration files
- 5 **Clinical trials:** perform small-scale clinical trials to gain scientific data
- 6 **IP:** Secure IP across the value chain




Creso Pharma Ltd: Business Model




Creso: Near-Term Revenues

Product Development and Launches are in process and on track




Animal health product launches in the EU in 2017



Human health product launches in the EU in 2018



Medicinal Cannabis in Australia



Hemp Industries products organic growth off a small base

Next 12 Months



Assess North American biopharmaceutical company



Global product and market development - launch readiness

Q2CY2017



Pioneer Medicinal Cannabis in Australia



Launch of first animal health product for horses in EU



Launch of first animal health product for dogs in EU

Q3CY2017



Launch of first-generation human health nutraceutical product for anxiety and stress based on INNutri technology



Launch of second-generation nutraceutical human health product for anxiety and stress based on Domaco buccal technology



Launch of animal health product for horses and dogs based on Domaco technology

CY2018

Investment Summary



Rapidly Growing Markets

- Increasing scientific evidence on efficacy of cannabis-based treatments
- Existing markets are expanding and new markets opening
- More countries are liberalising medicinal cannabis

Increased Consumer Demand



Strongly Performing Sector

- Investor interest in sector is strong
- 50+ companies with business based largely on legal marijuana
- Industry in infancy with plenty of room to grow

Strong Sales Revenue



"Gold Standard"

- Creso brings pharmaceutical industry rigour and professionalism to medicinal cannabis market
- Company well placed to be the gold standard in cannabis and hemp derived therapeutics

Industry Leadership



Sound Business Model

- Near-term revenues
- Diversified revenue streams from human and pet health markets
- Best practice for CBD extraction and drug delivery
- Resources in place for global sales

Strong Company Returns

Contact Information

For more information please contact:

Creso Pharma Limited

t: +61 8 6381 0054

a: Level 4, 11 Ventnor Avenue
West Perth WA Australia

Mirador Corporate

Company Secretary

t: +61 8 6381 0054

a: Level 4, 11 Ventnor Avenue
West Perth WA Australia

EverBlu Capital

Corporate Advisor

t: 02 8249 0000

e: info@everblucapital.com

w: www.everblucapital.com

a: Level 39, Aurora Place,
88 Phillip Street,
Sydney NSW Australia



Questions